Home > Publications database > Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis. > print

001     177382
005     20240917144149.0
024 7 _ |a 10.3389/fonc.2021.757664
|2 doi
024 7 _ |a pmid:34760702
|2 pmid
024 7 _ |a pmc:PMC8574071
|2 pmc
024 7 _ |a altmetric:115744303
|2 altmetric
037 _ _ |a DKFZ-2021-02474
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Khandanpour, Cyrus
|b 0
245 _ _ |a Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis.
260 _ _ |a Lausanne
|c 2021
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726576882_21166
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Transcription factor Growth Factor Independence 1 (GFI1) regulates the expression of genes important for survival, proliferation and differentiation of hematopoietic cells. A single nucleotide polymorphism (SNP) variant of GFI1 (GFI1-36N: serine replaced by asparagine at position 36), has a prevalence of 5-7% among healthy Caucasians and 10-15% in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) predisposing GFI-36N carriers to these diseases. Since GFI1 is implicated in B cell maturation and plasma cell (PC) development, we examined its prevalence in patients with multiple myeloma (MM), a haematological malignancy characterized by expansion of clonal PCs. Strikingly, as in MDS and AML, we found that the GFI1-36N had a higher prevalence among MM patients compared to the controls. In subgroup analyses, GFI1-36N correlates to a shorter overall survival of MM patients characterized by the presence of t(4;14) translocation and gain of 1q21 (≤3 copies). MM patients carrying gain of 1q21 (≥3 copies) demonstrated poor progression free survival. Furthermore, gene expression analysis implicated a role for GFI1-36N in epigenetic regulation and metabolism, potentially promoting the initiation and progression of MM.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Gfi1
|2 Other
650 _ 7 |a SNP variant
|2 Other
650 _ 7 |a multiple myeloma
|2 Other
650 _ 7 |a prevalance
|2 Other
650 _ 7 |a prognosis
|2 Other
700 1 _ |a Eisfeld, Christine
|b 1
700 1 _ |a Nimmagadda, Subbaiah Chary
|b 2
700 1 _ |a Raab, Marc S
|b 3
700 1 _ |a Weinhold, Niels
|b 4
700 1 _ |a Seckinger, Anja
|b 5
700 1 _ |a Hose, Dirk
|b 6
700 1 _ |a Jauch, Anna
|b 7
700 1 _ |a Försti, Asta
|0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
|b 8
|u dkfz
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 9
|u dkfz
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 10
|u dkfz
700 1 _ |a Hummel, Manuela
|0 P:(DE-He78)fae4f3c76bbbd2fc21dd920b46945d42
|b 11
700 1 _ |a Lenz, Georg
|b 12
700 1 _ |a Goldschmidt, Hartmut
|b 13
700 1 _ |a Huhn, Stefanie
|b 14
773 _ _ |a 10.3389/fonc.2021.757664
|g Vol. 11, p. 757664
|0 PERI:(DE-600)2649216-7
|p 757664
|t Frontiers in oncology
|v 11
|y 2021
|x 2234-943X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177382
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)fae4f3c76bbbd2fc21dd920b46945d42
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT ONCOL : 2019
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-01-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-01-27
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-01-27
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-27
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-27
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)C050-20160331
|k C050
|l Molekular-Genetische Epidemiologie
|x 2
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C050-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21